IP Library › Granted Patent US 12,240,853
Granted Patent B2
US 12,240,853 · App. 16/865,678 · Granted Mar 4, 2025

Compounds useful in HIV therapy

Inventors: John F. Miller (Research Triangle Park, NC); Emile Johann Velthuisen (Research Triangle Park, NC)
Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
C07D473/34A61K9/0019A61K31/70A61K45/06A61P31/18C07D487/04C07H19/16C07H19/173
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,853
App. No.
16/865,678
Granted
Mar 4, 2025
Kind
B2
Abstract

The invention relates to a compound of the formula: salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

Claims (17)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A compound having the structure:

3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

4. The composition of claim 3 , wherein the composition is present in parenteral form.

5. The composition of claim 3 , wherein the composition is in a tablet form.

6. The composition of claim 3 , wherein the composition is formulated as a long acting parenteral injection.

7. The composition of claim 3 , wherein the composition is a nano-particle composition.

8. A pharmaceutical composition comprising a compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

9. The composition of claim 8 , wherein the composition is present in parenteral form.

10. The composition of claim 8 , wherein the composition is in a tablet form.

11. The composition of claim 8 , wherein the composition is formulated as a long acting parenteral injection.

12. The composition of claim 8 , wherein the composition is a nano-particle composition.

13. A kit comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 .

14. A kit comprising the compound according to claim 2 .

15. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 070854/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: MILLER, JOHN FRANKLIN; VELTHUISEN, EMILE JOHANN
To: GLAXOSMITHKLINE LLC
Reel/Frame 065551/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: GLAXOSMITHKLINE LLC
To: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
Reel/Frame 065551/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
Reel/Frame 065551/0152 →
Continuity (2)
Provisional Application 62814316 · Mar 6, 2019
Related Publication 20230174534A1 · Jun 8, 2023
References Cited (86)
US 7339053B2 · Kohgo et al. · 2008 [cited by applicant]
US 7625877B2 · Kohgo et al. · 2009 [cited by applicant]
US 8039614B2 · Kohgo et al. · 2011 [cited by applicant]
US 8835615B2 · Chang · 2014 [cited by applicant]
US 8877731B2 · Beigelman et al. · 2014 [cited by applicant]
US 8927513B2 · Manoharan et al. · 2015 [cited by applicant]
US 9073960B2 · Beigelman et al. · 2015 [cited by applicant]
US 9198972B2 · Manoharan et al. · 2015 [cited by applicant]
US 9296777B2 · Sofia · 2016 [cited by applicant]
US 9346848B2 · Beigelman et al. · 2016 [cited by applicant]
US 9441007B2 · Wang et al. · 2016 [cited by applicant]
US 9566340B2 · Manoharan et al. · 2017 [cited by applicant]
US 9603863B2 · Blatt et al. · 2017 [cited by applicant]
US 9603864B2 · Blatt et al. · 2017 [cited by applicant]
US 9676808B2 · Du et al. · 2017 [cited by applicant]
US 9725479B2 · Manoharan et al. · 2017 [cited by applicant]
US 9770035B2 · Narva et al. · 2017 [cited by applicant]
US 9890188B2 · Wang et al. · 2018 [cited by applicant]
US 10307439B2 · Blatt et al. · 2019 [cited by applicant]
US 10537589B2 · Hazuda et al. · 2020 [cited by applicant]
US 20050215512A1 · Kohgo · 2005 [cited by examiner]
US 20150274767A1 · Girijavallabhan et al. · 2015 [cited by applicant]
US 20150366887A1 · Blatt et al. · 2015 [cited by applicant]
US 20150366888A1 · Blatt et al. · 2015 [cited by applicant]
US 20180055867A1 · Hazuda et al. · 2018 [cited by applicant]
US 20190022115A1 · Girijavallabhan et al. · 2019 [cited by applicant]
US 20190185508A1 · Alexandrea et al. · 2019 [cited by applicant]
EP 1589026 · 2008 [cited by applicant]
EP 2177527A1 · 2010 [cited by applicant]
WO WO0069876 · 2000 [cited by applicant]
WO WO2003035012 · 2003 [cited by applicant]
WO WO2020031131 · 2013 [cited by applicant]
WO WO13096679 · 2013 [cited by applicant]
WO WO13142525 · 2013 [cited by applicant]
WO WO2014209979 · 2014 [cited by applicant]
WO WO2015054465 · 2015 [cited by applicant]
WO 2015143712A1 · 2015 [cited by applicant]
WO WO2015148746 · 2015 [cited by applicant]
WO 2016057866A1 · 2016 [cited by applicant]
WO 2016066283A1 · 2016 [cited by applicant]
WO WO2016100569 · 2016 [cited by applicant]
WO WO2017053216 · 2017 [cited by applicant]
WO WO2017139519A1 · 2017 [cited by examiner]
WO 2017223280A2 · 2017 [cited by applicant]
WO 2018085307A1 · 2018 [cited by applicant]
WO WO2019171285 · 2019 [cited by applicant]
WO 2019199667A2 · 2019 [cited by applicant]
WO WO2020044257 · 2020 [cited by applicant]
WO 2020178798A1 · 2020 [cited by applicant]
Medication Safety An Essential Guide (Year: 2009). [cited by examiner]
Prodrugs and Targeted Delivery: Towards Better ADME Properties (Year: 2011). [cited by examiner]
Anderson et al, Journal of Controlled Release, vol. 19, No. 3, Mar. 1992, pp. 219-229. [cited by applicant]
Bibby David et al., International Journal of Pharmaceutics, vol. 144, No. 1, Sep. 1996, pp. 61-70. [cited by applicant]
Keykavous Parang et al., Nucleosides and Nucleotides, vol. 17, No. 6., Jun. 1998, pp. 990. [cited by applicant]
Lupia et al., Antimicrobial Agents and Chemotherapy, vol. 37, No. 4, Apr. 1993, pp. 818-824. [cited by applicant]
Masayuki Kageyama et al., Organic Letters, vol. 13, No. 19, Oct. 2011, pp. 5264-5266. [cited by applicant]
Parang et al., Antiviral Chemistry and Chemother International Medical Press, vol. 9., No. 4, Jan. 1998, pp. 311-323. [cited by applicant]
U.S. Appl. No. 62/639,667, filed Mar. 7, 2018. [cited by applicant]
U.S. Appl. No. 62/716,494, filed Aug. 9, 2018. [cited by applicant]
U.S. Appl. No. 62/884,191, filed Aug. 8, 2019. [cited by applicant]
U.S. Appl. No. 62/892,577, filed Aug. 28, 2019. [cited by applicant]
U.S. Appl. No. 62/993,300, filed Mar. 23, 2020. [cited by applicant]
U.S. Appl. No. 62/724,647, filed Aug. 30, 2018. [cited by applicant]
Agarwal, H.K., et al. “Emtricitabine Prodrugs with Improved Anti-HIV Activity and Cellular Uptake.” Molecular Pharmaceutics; 2013; pp. 467-476; vol. 10(2). [cited by applicant]
Dabrowska-Mas, “Insights on Fatty Acids in Lipohilic Prodrug Strategy.” Internationsl Research Journal of Pure and Applied Chemistry; 2017; pp. 2-5; vol. 14(4). [cited by applicant]
Irby, D., et al., “Lipid-Drug Conjugate for Enhancing Drug Delivery” Molecular Pharmaceutics; 2017; pp. 1325-1338; vol. 14(5). [cited by applicant]
Krovi, et al., “Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.” International Journal of Pharmacecutics; 2018; pp. 371-377; vol. 552(1-2). [cited by applicant]
PCT/IB2019/051799, Third Party Observations, dated Jul. 7, 2020. [cited by applicant]
“ViiV Healthcare Announces Investigational Injectable Cabotegravir is Superior to Oral Standard of Care for HIV Prevention in Women,” HIV Articles, https://www.natap.org/2020/HIV/110920_01.htm (4 pages). [cited by applicant]
“ViiV Healthcare Announces Superior Efficacy of Investigational, Long-Acting Injectable Formulation of Cabotegravir Dosed Every Two Months over Daily Oral PrEP,” Businesswire, https://www.businesswire.com/news/home/2020… [cited by applicant]
Barrett et al., “Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention,” Antimicrobial Agents and Chemotherapy 2018, vol. 62, issue 10, e01058-18 (13 pages). [cited by applicant]
Gulick et al., “Long-Acting HIV Drugs for Treatment and Prevention,” Annu. Rev. Med. 2019. 70:137-150. [cited by applicant]
Remnar, “Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics,” Molecular Pharmaceutics, 2014, 11, pp. 1739-1749. [cited by applicant]
Senter et al., “The Role of Rat Serum Carboxylesterase in the Activation of Paclitaxel and Camptothecin Prodrugs,” Cancer Research 56, 1996, pp. 1471-1474. [cited by applicant]
Banerjee et al., “Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design and Applications”, Journal of Drug Delivery, Hindawi Publishing Corporation, vol. 2012, 2012, pp. 1-17. [cited by applicant]
U.S. Appl. No. 62/639,667, filed Mar. 7, 2018/ GlaxoSmithKline Intellectual Property No. 2 Ltd. [cited by applicant]
U.S. Appl. No. 62/716,494, filed Aug. 9, 2018/ GlaxoSmithKline Intellectual Property No. 2 Ltd. [cited by applicant]
U.S. Appl. No. 62/724,647, filed Aug. 30, 2018/ GlaxoSmithKline Intellectual Property No. 2 Ltd. [cited by applicant]
U.S. Appl. No. 62/814,316, filed Mar. 6, 2019/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
U.S. Appl. No. 62/884,191, filed Aug. 8, 2019/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
U.S. Appl. No. 62/892,577, filed Aug. 28, 2019/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
U.S. Appl. No. 62/993,300, filed Mar. 23, 2020/ ViiV Healthcare Company. [cited by applicant]
WO 2019/171285/Sep. 12, 2019/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
WO 2020/031131/Feb. 13, 2020/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
WO 2020/044257/Mar. 5, 2020/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]
PCT/IB2020/051878/Mar. 4, 2020/ GlaxoSmithKline Intellectual Property No. 2 Ltd. and ViiV Healthcare Company. [cited by applicant]